Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

41.26 -0.73 (-1.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 843,391
Open 41.78
Bid (Size) 40.34 (1)
Ask (Size) 41.99 (1)
Prev. Close 41.99
Today's Range 41.23 - 42.06
52wk Range 34.32 - 54.44
Shares Outstanding 141,797,854
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Latest Analyst Ratings For Ionis Pharmaceuticals
Via Benzinga
Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows
Ionis Pharmaceuticals reports positive Phase 2 results for ION224, showing significant improvement in MASH and liver histology without worsening fibrosis. Safe and well-tolerated treatment with... 
Via Benzinga

Performance

YTD
-21.96%
-21.96%
1 Month
-6.10%
-6.10%
3 Month
-20.67%
-20.67%
6 Month
-6.23%
-6.23%
1 Year
+15.64%
+15.64%

More News

Read More
Are These 5 Undervalued Stocks Ready to Break Out?
Via MarketBeat
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
From Biogen Inc.
Via GlobeNewswire
Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals
Via Benzinga
Earnings Scheduled For February 21, 2024
Via Benzinga
JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
Via Benzinga
Exposures Product Safety
Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study
Via Benzinga
Exposures Product Safety
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts
Via Benzinga
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Where Ionis Pharmaceuticals Stands With Analysts
Via Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
Via Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Via Investor's Business Daily
2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
Via Benzinga
Topics ETFs
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies
Via InvestorPlace
Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential
Via Benzinga
Exposures Product Safety
New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment
Via Benzinga
Exposures Product Safety
Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach
Via Benzinga
Based on good technical signals, IONIS PHARMACEUTICALS INC is potentially setting up for a breakout.
Via Chartmill
Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Technical Insights for IONIS PHARMACEUTICALS INC (NASDAQ:IONS): Is a Breakout Imminent?
Via Chartmill
Cathie Wood's Ark Invest Goes Shopping For Moderna Stock — Sells DraftKings Shares Amid Quarterly Rise In Revenue, EPS Beat
Via Benzinga
Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.